| 6982- | Form, | Formononetin: A Review of Its Anticancer Potentials and Mechanisms |
| - | Review, | Var, | NA |
| 6983- | Form, | Formononetin enhances angiogenesis in diabetic wounds by inhibiting ferroptosis through suppression of mtROS-mediated xCT/GPX4 upregulation |
| - | vitro+vivo, | Nor, | HUVECs | - | vitro+vivo, | Diabetic, | NA |
| 6984- | Form, | Formononetin suppresses colitis-associated colon cancer by targeting lipid synthesis and mTORC2/Akt signaling |
| - | in-vitro, | Colon, | HCT116 | - | Review, | IBD, | RAW264.7 |
| 6985- | Form, | Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 |
| 6986- | Form, | Anti-angiogenesis Function of Ononin via Suppressing the MEK/Erk Signaling Pathway |
| - | in-vitro, | NA, | NA |
| 6987- | Form, | Formononetin exhibits anticancer activity in gastric carcinoma cell and regulating miR-542-5p |
| - | vitro+vivo, | GC, | SGC-7901 | - | in-vitro, | BC, | MGC803 |
| 6988- | Form, | Formononetin ameliorates high glucose‑induced endothelial dysfunction by inhibiting the JAK/STAT signaling pathway |
| - | in-vitro, | Nor, | HUVECs |
| - | in-vitro, | Nor, | HUVECs |
| 6991- | Form, | Formononetin-induced apoptosis of human prostate cancer cells through ERK1/2 mitogen-activated protein kinase inactivation |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 6992- | Form, | Formononetin: pharmacological properties and therapeutic potential |
| - | Review, | Nor, | NA |
| 6970- | Form, | Formononetin, an isoflavone from Astragalus membranaceus inhibits proliferation and metastasis of ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA |
| 6997- | Form, | PI, | Formononetin–piperine–phospholipid complex: enhancement of anti-osteoporotic activity and bioavailability in bone marrow in rats |
| - | in-vivo, | ostP, | NA |
| 6996- | Form, | MET, | Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro |
| - | in-vitro, | BC, | MCF7 |
| 6995- | Form, | Formononetin inhibits neuroinflammation and increases estrogen receptor beta (ERβ) protein expression in BV2 microglia |
| - | Review, | Nor, | BV2 |
| 6993- | Form, | ISL, | Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell |
| - | in-vitro, | CRC, | HCT116 |
| 6976- | Form, | Study on the Mechanism of Formononetin Against Hepatocellular Carcinoma: Regulating Metabolic Pathways of Ferroptosis and Cell Cycle |
| - | vitro+vivo, | HCC, | HepG2 |
| 6963- | Form, | Formononetin-induced apoptosis by activation of Ras/p38 mitogen-activated protein kinase in estrogen receptor-positive human breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D |
| 6964- | Form, | Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo |
| - | vitro+vivo, | BC, | MCF7 |
| 6965- | Form, | Formononetin inhibits colon carcinoma cell growth and invasion by microRNA‑149‑mediated EphB3 downregulation and inhibition of PI3K/AKT and STAT3 signaling pathways |
| - | in-vitro, | CRC, | HCT116 |
| 6966- | Form, | Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model |
| - | NA, | MM, | NA |
| 6967- | Form, | BTZ, | Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model |
| - | in-vivo, | Melanoma, | U266 | - | in-vivo, | Melanoma, | RPMI-8226 |
| 6968- | Form, | Formononetin represses cervical tumorigenesis by interfering with the activation of PD-L1 through MYC and STAT3 downregulation |
| - | in-vitro, | Cerv, | NA |
| 6969- | Form, | Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer |
| - | vitro+vivo, | NSCLC, | HCC827 | - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | H1299 |
| 6977- | Form, | Differential ability of formononetin to stimulate proliferation of endothelial cells and breast cancer cells via a feedback loop involving MicroRNA-375, RASD1, and ERα |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | BT474 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | HUVECs |
| 6971- | Form, | In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa |
| - | vitro+vivo, | Cerv, | HeLa |
| 6972- | Form, | PacT, | Formononetin ameliorates the drug resistance of Taxol resistant triple negative breast cancer by inhibiting autophagy |
| - | in-vivo, | BC, | MDA-MB-231 |
| 6973- | Form, | Formononetin enhances the chemosensitivity of triple negative breast cancer via BTB domain and CNC homolog 1-mediated mitophagy pathways |
| - | Human, | BC, | NA |
| 6974- | Form, | Formononetin Defeats Multidrug-Resistant Cancers by Induction of Oxidative Stress and Suppression of P-Glycoprotein |
| - | in-vitro, | Cerv, | HeLa |
| 6975- | Form, | Formononetin inhibits colorectal cancer via the miR-490-3p/ABCC2 axis and synergizes with 5-fluorouracil: mechanistic insights and therapeutic implications |
| - | vitro+vivo, | CRC, | NA |
| 8306- | FS, | lign, | Flax Lignans: From Biosynthetic Regulation to Biological Activities |
| - | Review, | NA, | NA |
| 8307- | FS, | lign, | Efficacy and safety of a flaxseed hull extract in the symptomatic management of benign prostatic hyperplasia: a parallel, randomized, double-blind, placebo-controlled, pilot study |
| - | Trial, | BPH, | NA |
| 8304- | FS, | Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer |
| - | Trial, | Pca, | NA |
| 8303- | FS, | The relative bioavailability of enterolignans in humans is enhanced by milling and crushing of flaxseed |
| - | Trial, | Nor, | NA |
| - | in-vivo, | BPH, | NA |
| 8310- | FS, | Can flaxseed “milk” prevent anthracycline mediated cardiotoxicity in women with breast cancer (CANFLAX-BC)? |
| - | Trial, | BC, | NA |
| 8300- | FS, | Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery |
| - | Trial, | Pca, | NA |
| 8313- | FS, | Flaxseed and its lignan and oil components: can they play a role in reducing the risk of and improving the treatment of breast cancer? |
| - | Review, | BC, | NA |
| 8315- | FS, | Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen |
| - | Trial, | Pca, | NA | - | Trial, | BPH, | NA |
| 8581- | FS, | Dietary Modulation of the Human Gut Microbiota and Metabolome with Flaxseed Preparations |
| - | in-vivo, | Nor, | NA |
| 8580- | FS, | Anti-Cancer Properties of Flaxseed Proteome |
| - | Review, | Var, | NA |
| 8579- | FS, | IP6, | Flaxseed: a potential source of food, feed and fiber |
| - | Review, | Nor, | NA | - | Review, | IBD, | NA |
| 8578- | FS, | High alpha-linolenic acid flaxseed (Linum usitatissimum): some nutritional properties in humans |
| - | Human, | Nor, | NA |
| 948- | Fuc, | Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia |
| - | vitro+vivo, | Bladder, | T24/HTB-9 | - | in-vitro, | Nor, | HUVECs |
| 1039- | Fuc, | Anti-Proliferative and Pro-Apoptotic vLMW Fucoidan Formulas Decrease PD-L1 Surface Expression in EBV Latency III and DLBCL Tumoral B-Cells by Decreasing Actin Network |
| - | in-vitro, | NA, | NA |
| 1114- | Fuc, | The Potential Effect of Fucoidan on Inhibiting Epithelial-to-Mesenchymal Transition, Proliferation, and Increase in Apoptosis for Endometriosis Treatment: In Vivo and In Vitro Study |
| - | vitro+vivo, | NA, | NA |
| 1038- | Fuc, | immuno, | Fucoidan enhances the anti-tumor effect of anti-PD-1 immunotherapy by regulating gut microbiota. |
| - | in-vivo, | BC, | NA |
| 1155- | Fuc, | The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations |
| - | Review, | NA, | NA |
| 7010- | Fuc, | Fucoidan enhances the effect of chemotherapeutic drug against drug-resistant lung cancer cells |
| - | in-vitro, | Lung, | NA |
| 7011- | Fuc, | ATO, | VitA,RetA, | Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo |
| - | NA, | APL, | APL NB4 | - | vitro+vivo, | NA, | NA |
| 7012- | Fuc, | Fucoidan: A promising natural therapeutic agent for protecting human kidney health |
| - | Review, | EC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid